Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RNXT | US
0.01
1.56%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.89
0.91
0.94
0.88
RenovoRx Inc. a clinical-stage biopharmaceutical company focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos California.
View LessStrength based on increasing price with high volume
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
91.5%1 month
76.5%3 months
71.7%6 months
71.9%-
-
2.59
-
-
-4.72
-
-
-11.39M
21.24M
21.24M
-
-
-
-
-155.12
2.30
0.49
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.15
Range1M
0.22
Range3M
0.53
Rel. volume
1.25
Price X volume
380.42K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.299 | 22.62M | 4.55% | n/a | 4.33% |
| Reviva Pharmaceuticals Holdings Inc. | RVPH | Biotechnology | 0.669 | 22.14M | -6.43% | n/a | 0.00% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 2.1 | 21.41M | -42.62% | n/a | 2.12% |
| Evaxion Biotech A/S | EVAX | Biotechnology | 3.73 | 20.81M | 5.07% | n/a | 837.11% |
| Dyadic International Inc | DYAI | Biotechnology | 0.699 | 20.60M | -1.63% | n/a | 175.64% |
| InMed Pharmaceuticals Inc | INM | Biotechnology | 1.54 | 20.54M | -2.53% | n/a | 7.00% |
| DOMH | DOMH | Biotechnology | 3.17 | 19.90M | 2.26% | n/a | 7.66% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 3.08 | 18.78M | -0.32% | n/a | 0.00% |
| QNRX | QNRX | Biotechnology | 4.57 | 18.19M | 1.78% | n/a | 43.11% |
| CELU | CELU | Biotechnology | 0.812 | 17.85M | -6.91% | n/a | 127.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.1 | 16.07M | 7.84% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.72 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.59 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 71.73 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 21.24M | 3.66B | Emerging |